Search Results - Tarek A. Hammad

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights by Priyanka Chhikara, Tarek A. Hammad

    Published in Frontiers in Drug Safety and Regulation (2025-09-01)
    Get full text
    Article


  2. 2

    Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence by Tarek A. Hammad, Simon Davis, Salman Afsar

    Published in Frontiers in Drug Safety and Regulation (2024-08-01)
    Get full text
    Article


  3. 3

    Achieving synchrony: bridging the gap between pharmaceutical companies and regulators on safety labeling updates by Tarek A. Hammad, Sasan Sabrdaran, Jean-Marie Heim

    Published in Frontiers in Drug Safety and Regulation (2024-09-01)
    Get full text
    Article


  4. 4

    Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action by Tarek A. Hammad, Melissa Naylor, Dona M. Ely, Simon Davies

    Published in Frontiers in Pharmacology (2025-04-01)
    Get full text
    Article


  5. 5

    Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirements by Tarek A. Hammad, Salman Afsar, Herve Le-Louet, Herve Le-Louet, Veronique F. Kugener

    Published in Frontiers in Drug Safety and Regulation (2023-09-01)
    Get full text
    Article


  6. 6

    Aspects to consider in causality assessment of safety signals: broadening the thought process by Tarek A. Hammad, Salman Afsar, Laura B. McAvoy, Hervé Le Louet, Hervé Le Louet

    Published in Frontiers in Drug Safety and Regulation (2023-05-01)
    Get full text
    Article


  7. 7

    Reflections, operational lessons, and practical insights from a pharmacovigilance inspection: a case example of organizational strategies for medical safety readiness by Tarek A. Hammad, Sasan Sabrdaran, Hesham Aboshady, Raquel Rogers, Jean-Marie Heim, Kim Bullano, Tatiana Ishida

    Published in Therapeutic Advances in Drug Safety (2025-08-01)
    Get full text
    Article


  8. 8

    How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action by Rosanne Janssens, Liese Barbier, Mireille Muller, Irina Cleemput, Isabelle Stoeckert, Chiara Whichello, Bennett Levitan, Tarek A. Hammad, Charis Girvalaki, Juan-Jose Ventura, Karin Schölin Bywall, Karin Schölin Bywall, Cathy Anne Pinto, Elise Schoefs, Eva G. Katz, Ulrik Kihlbom, Isabelle Huys

    Published in Frontiers in Pharmacology (2023-08-01)
    Get full text
    Article


Search Tools: